Everest Clinical Research and CeleCor Therapeutics Named Finalists for Partnership of the Year Award
TORONTO – October 22, 2026 – Everest Clinical Research and CeleCor Therapeutics have been named finalists for Sponsor/Service Provider Partnership of the Year at the Citeline Biotech Awards 2026, recognizing their collaboration on the global Phase III CeleBrate trial evaluating zalunfiban (Disaggpro™) for ST-elevation myocardial infarction (STEMI).
The partnership brought together CeleCor’s scientific and clinical vision with Everest’s operational expertise to execute a complex global study that required treatment to be administered within minutes of first medical contact. Together, the teams developed country-specific enrollment and consent pathways that not only met regulatory standards but also enabled enrollment in emergency care environments across diverse healthcare systems in six countries.
The CeleBrate trial ultimately met its primary efficacy and safety endpoints, showing rapid zalunfiban treatment for STEMI heart attacks reduced the risk of cardiovascular events over the 30 days following treatment. The results of the study were published in The New England Journal of Medicine Evidence. CeleCor’s NDA for zalunfiban was accepted by the FDA on September 30, 2026, with a PDUFA target action date of June 18, 2027, marking another significant milestone for the program.
The winner of the Partnership of the Year Award will be announced in Boston on November 12.
